CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy

Neoplasia (United States)

Volumn 14, Issue 8, 2012, Pages 709-718

  Domanska, Urszula M ^a   Timmer Bosscha, Hetty ^a   Nagengast, Wouter B ^a   Oude Munnink, Thijs H ^a   Kruizinga, Roeliene C ^a   Ananias, Hildo J K ^a   Kliphuis, Nathalie M ^a   Huls, Gerwin ^a   De Vries, Elisabeth G E ^a   De Jong, Igle J ^a   Walenkamp, Annemiek M E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DOCETAXEL; MONOCLONAL ANTIBODY; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; STROMAL CELL DERIVED FACTOR 1 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIZATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 84865203915     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12324     Document Type: Article

References (40)

1. Zlotnik A (2006). Chemokines and cancer. Int J Cancer 119, 2026-2029.
2. Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, and Fuse H (2008). Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci 99, 539-542.
3. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, and Castello G (2005). Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11, 1835-1841.
4. Yopp AC, Shia J, Butte JM, Allen PJ, Fong Y, Jarnagin WR, Dematteo RP, and D'Angelica MI (in press). CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. Ann Surg Oncol.
5. Salvucci O, Bouchard A, Baccarelli A, Deschenes J, Sauter G, Simon R, Bianchi R, and Basik M (2006). The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 97, 275-283.
6. Burger JA and Peled A (2009). CXCR4 antagonists: targeting the microenviron-ment in leukemia and other cancers. Leukemia 23, 43-52.
7. Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A, Ratajczak J, and Ratajczak MZ (2005). Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23, 879-894.
8. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, et al. (2007). Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25, 1315-1321.
9. Dillmann F, Veldwijk MR, Laufs S, Sperandio M, Calandra G, Wenz F, Zeller J, and Fruehauf S (2009). Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to imatinib and nilotinib. Leuk Lymphoma 50, 1676-1686.
10. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, et al. (2009). Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113, 6206-6214.
11. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, and Burger JA (2005). Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106, 1824-1830.
12. Kim M, Koh YJ, Kim KE, Koh BI, Nam DH, Alitalo K, Kim I, and Koh GY (2010). CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res 70, 10411-10421.
13. Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, Alsawafi Y, Mourskaia AA, Siegel PM, Salvucci O, et al. (2011). CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 129, 225-232.
14. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121, 1298-1312.
15. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, and Weinberg RA (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348.
16. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, and Cunha GR (1999). Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59, 5002-5011.
17. Ferlay J, Parkin DM, and Steliarova-Foucher E (2010). Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46, 765-781.
18. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, et al. (2011). EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59, 61-71.
19. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, et al. (2011). EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59, 572-583.
20. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351, 1502-1512.
21. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147-1154.
22. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, and McCauley LK (2002). Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62, 1832-1837.
23. Meads MB, Hazlehurst LA, and Dalton WS (2008). The bone marrow micro-environment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14, 2519-2526.
24. de Vries EGE, Meijer C, Timmer-Bosscha H, Berendsen HH, de Leij L, Scheper RJ, and Mulder NH (1989). Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res 49, 4175-4178.
25. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, and Logsdon CD (2008). Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68, 918-926.
26. Franco OE, Jiang M, Strand DW, Peacock J, Fernandez S, Jackson RS II, Revelo MP, Bhowmick NA, and Hayward SW (2011). Altered TGF-beta signaling in a subpopula-tion of human stromal cells promotes prostatic carcinogenesis. Cancer Res 71, 1272-1281.
27. Gilbert LA and Hemann MT (2010). DNA damage-mediated induction of a chemoresistant niche. Cell 143, 355-366.
28. Konopleva MY and Jordan CT (2011). Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 29, 591-599.
29. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, and McCauley LK (2002). Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62, 1832-1837.
30. De Clercq E (2009). The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 77, 1655-1664.
31. Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, Urbanek C, Wong D, Goodison S, and Rosser CJ (2009). Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 69, 1460-1469.
32. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, and Luker GD (2004). CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64, 8604-8612.
33. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, and Lucci A (2009). A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155, 231-236.
34. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, and Segal RA (2003). A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 100, 13513-13518.
35. Redjal N, Chan JA, Segal RA, and Kung AL (2006). CXCR4 inhibition syner-gizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res 12, 6765-6771.
36. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, and Brown JM (2010). Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120, 694-705.
37. Uy GL, Rettig MP, McFarland KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein K, Vij R, Westervelt P, et al. (2008). Mobilization and chemosensitization of AML with the CXCR4 antagonist plerixafor (AMD3100): a phase I/II study of AMD3100 + MEC in patients with relapsed or refractory disease. Blood 112, 678.
38. Uy GL, Rettig MP, McFarland K, Hladnik L, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein K, Vij R, Westervelt P, et al. (2009). A phase I/II study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory AML. Blood 114, 787.
39. Andritsos L, Byrd JC, Jones JA, Hewes B, Kipps TJ, Hsu FJ, and Burger JA (2010). Preliminary results from a phase I dose escalation study to determine the maximum tolerated dose of plerixafor in combination with rituximab in patients with relapsed chronic lymphocytic leukemia. Haematologica 116, 321.
40. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, and Casanovas O (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231.